Co-Ultramicronized Palmitoylethanolamide/Luteolin-Induced Oligodendrocyte Precursor Cell Differentiation is Associated With Tyro3 Receptor Upregulation
Laboratory studyOther animalsWith luteolin (co-ultramicronised PEA/luteolin, PEALut)
This study tested palmitoylethanolamide together with luteolin (co-ultramicronised PEA/luteolin, PEALut). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- Cultured oligodendrocyte precursor cells (OPCs), followed from day 2 in vitro through the first week
- Dose used in the study
- Co-ultramicronised PEALut applied to cell cultures; concentration not stated in the abstract
- Duration
- Up to one week in vitro
- What was measured
- mRNA expression of TAM receptors Tyro3, Axl and Mertk during OPC differentiation, and the effect of the mTOR inhibitor rapamycin on this and on myelin protein expression
What the authors reported
Tyro3 mRNA rose during OPC differentiation and PEALut increased this rise further, while reducing Axl and Mertk expression. Rapamycin blocked oligodendrocyte differentiation and myelin protein (MBP, CNPase) expression, and PEALut given after rapamycin prevented this block, preserving Tyro3, MBP and CNPase levels.
Limits of this study
A cell-culture study; it cannot show effect in people or animals. One author was employed by Epitech Group SpA, which makes ultramicronised PEA products; the other authors declare no conflicts.
Source
PubMed 34276381 · doi:10.3389/fphar.2021.698133
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.